These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11730262)

  • 1. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.
    Ringe JD; Rovati LC
    Calcif Tissue Int; 2001 Oct; 69(4):252-5. PubMed ID: 11730262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fluorides and bisphosphonates in the treatment of osteoporosis].
    Ringe JD
    Orthopade; 2001 Jul; 30(7):456-61. PubMed ID: 11515184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis: trials and tribulations.
    Seeman E
    Am J Med; 1997 Aug; 103(2A):74S-87S; discussion 87S-89S. PubMed ID: 9302899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
    Cortet B; Béra-Louville A; Gauthier P; Gauthier A; Marchandise X; Delcambre B
    Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents.
    Wimalawansa SJ
    J Clin Densitom; 2000; 3(2):187-201. PubMed ID: 10871912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
    Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
    Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
    Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
    J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
    Lems WF; Jacobs JW; Bijlsma JW; van Veen GJ; Houben HH; Haanen HC; Gerrits MI; van Rijn HJ
    Ann Rheum Dis; 1997 Jun; 56(6):357-63. PubMed ID: 9227164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A; Snelder AA; Mulder H
    Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect on bone density in male osteoporosis of postmenopausal osteoporosis treatment (fluoride, etidronate, and calcitriol).
    Laroche M; Andrieu V; Constantin A; Mazières B
    Clin Exp Rheumatol; 1998; 16(6):760. PubMed ID: 9844778
    [No Abstract]   [Full Text] [Related]  

  • 13. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
    Beauchesne MF; Miller PF
    Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.
    Devogelaer JP
    Drug Saf; 1998 Aug; 19(2):141-54. PubMed ID: 9704250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates and osteoporosis treatment in Italy.
    Gennari C; Reginster JY
    Aging (Milano); 1998 Aug; 10(4):284-94. PubMed ID: 9825019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study.
    Ringe JD; Dorst A; Faber H; Kipshoven C; Rovati LC; Setnikar I
    Rheumatol Int; 2005 May; 25(4):296-300. PubMed ID: 15770482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
    Anderson FH; Francis RM; Bishop JC; Rawlings DJ
    Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD; Kipshoven C; Cöster A; Umbach R
    Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.